Baruch D. Kuppermann

Professor of Ophthalmology and Biomedical Engineering; Chief, Retina Service; Vice-Chair, Clinical Research, Ophthalmology
School of Medicine

M.D., University of Miami, Florida, 1985

Ph.D., California Institute of Technology, 1983, Neuroscience

Phone: Appointments (949) 824-2020; Academic Office (949) 824-6256
Fax: (949) 824-4015

University of California, Irvine
Gavin Herbert Eye Institute
850 Health Sciences Road
Mail Code: 4375
Irvine, CA 92697

picture of Baruch D. Kuppermann

1) Ocular Manifestations of AIDS 2) Risk factors for the development of retinopathy of prematurity post partum 3) Photodynamic therapy for the treatment of choroidal melanomas
After completing his Ph.D. in neuroscience at the California Institute of Technology (Cal Tech), Dr. Kuppermann went on to earn an M.D. at the University of Miami. He interned at LA County/USC Medical Center and did his residency in ophthalmology at USC’s Doheny Eye Institute. Dr. Kuppermann then went on to complete fellowships in Retina at both St. Joseph’s in Baltimore Maryland, and at the University of California, San Diego.

Following his fellowships he came to UCI and has been on faculty since 1992. He served as Acting Chairman of the Department of Ophthalmology at UCI from September 1995 to April 1996, and Interim Chairman from July 1, 1996 to December 1998. Currently he is a Professor and Chief of the Retina Service at UCI.

Dr. Kuppermann is the principal investigator at UCI for several multicenter national trials evaluating new drugs and devices for the treatment of diabetic retinopathy, age-related macular degeneration, and the ocular complications of AIDS. He is the national and international lead investigator for several of these trials. His primary area of research is drug delivery to the posterior segment of the eye, with special attention to the pharmacokinetics of the posterior segment. He has also developed models for viral retinal infections as well as for retinal angiogenesis and his research on these models using time release therapeutic agents may lead to new methods for the treatment of potentially blinding infections. In addition, Dr. Kuppermann has extensive research collaborations with pharmaceutical and biotechnology companies, serving as an advisor with a goal of bringing new treatments to patients for a variety of retinal diseases.

Dr Kuppermann is listed as one of the best doctors in America, and for the last several years in a row has been named as the "Best Ophthalmologist in Orange County" by Orange Coast Magazine. Dr. Kuppermann is a peer reviewer for the American Journal of Ophthalmology, Archives of Ophthalmology, Investigative Ophthalmology and Visual Science, Ophthalmology, Retina, Journal of Infectious Diseases, Lancet, and the Journal of Obstetrics and Gynecology.
Publications Non-peer review
  Kuppermann BD: Infectious and Inflammatory Retinitis. Oxford University Press 2011. Clinical Eye Atlas. Section 9: 700-25.
  Kuppermann BD: Differentiating Steroids Delivery Systems for Macular Edema. Johns Hopkins Advanced Studies in Ophthalmology. (7)2: 35-41 December 2010.
  Paganeli F, Cardillo JA, Dare AR, Melo LA Jr, Lucena DR, Silva AA Jr, Oliveira AG, Pizzolitto AC, Lavinsky D, Skaf M, Souza-Filho AA, Höfling-Lima AL, Nguyen QD, Kuppermann BD, Herrero-Vanrell R, Belfort R Jr for the Brazilian Ocular Pharmacology and Pharmaceutical Technology Research Group: Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. Expert Opin. Drug Deliv. (2010) 7(8):955-965.
  Kuppermann BD: Toxicity Studies on Triamcinolone Acetonide and Dexamethasone. Supplement to Retina Today May/June 2010; 13-14.
  Patil AJ, Sharma A, Kenney MC, Kuppermann BD: Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. Clinical Ophthalmology 2010:4 111-119.
  Chang-Lin J.-E; Attar M; Acheampong AA; Robinson MR; Whitcup SM; Kuppermann BD; Welty D: “Pharmacokinetics and Pharmadodynamics of a Sustained-Release Dexamethasone Intravitreal Implant”. Invest Opththalmol Vis Sci. 2011 Nov; 52 (1) 80-86.
  Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Osen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Won WT: “ Opthalmic Drug Delivery Systems for the Treatmant of Retinal Diseases: basic research to clinical applications”. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5403-20.
  Blumenkranz MS, Haller JA, Kuppermann BD, Williams GA, Ip M, Davis M, Weinberg DV, Chou C, Whitcup SM: “Correlation of Visual Acuity and Macular Thickness measured by Optical Coherence Tomography in patients with persistent Macular Edema”. Retina. July/August 2010; 30:1090-1094.
  Mansoor S, Gupta N, Patil AJ, Estrago- Franco MF, Ramirez C, Migon R, Sapkal A, Kuppermann BD, Kenney MC:” Inhibition of apoptosis in human retinal pigment epithelial cells treated with benzo(e)pyrene, a toxic component of cigarette smoke”. Invest Ophthalmol Vis Sci. 2010 May; 51(5):2601-7.
  Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS for The Dexamethasone DDS Phase II Study Group: “Intravitreous Dexamethasone Effects on Different Patterns of Diabetic Macular Edema”. Arch Ophthalmol. 2010 May;128(5) 642-3.
Grants “An evaluation of Intravitreal Ranibizumab for Bitreous Hemorrhage due to Porliferative Diabetic Retinopathy (protocol N)”. Jaeb. June 2010-Current.
“Development of an Office Based Real-time High Speed 3D Functional OCT System for Diagnosis of Retinal Diseases”. NIH-OCT Subaward. March 2011-Current.
“A Multicenter, Patient-masked, Safety extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System (Allergan 033D). Allergan. December 2010-Current.
“A 12 Month, Multicenter, Masked, Randomized,Controlled study to Assess the Safety and Efficacy of 700ug Ozurdex as Adjunctive Therapy to Lucentis compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to AMD (Allergan 021). Allergan. November 2010-Current.
“Controlled, Double Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD (RACE). Alcon Labs. August 2010-Current
American Academy of Ophthalmology
American Society of Retina Specialists
Macula Society
Pan American Association of Ophthalmology
Retina Society
Link to this profile
Last updated 07/07/2010